Authors


Chase Ibia, PharmD Candidate

Latest:

Common Patient Questions About Insulin Biosimilars Pertain to Classification

Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.


Susan Trieu, PharmD

Latest:

Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?

Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.


Brooke McCormick

Latest:

Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab Biosimilars

Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.


Ayaaz Hussain Khan, PhD

Latest:

Navigating Data Integrity for Generic Drug Approvals

Continuous innovation is required in various technological aspects to effectively manage the challenges of vast clinical data.


Justina Petrullo

Latest:

Dr Stephen Hanauer Gives Insight Into Growing US Adalimumab Market

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.


Jim Lichauer, PharmD, BCPS, FASHP

Latest:

The Promise of Biosimilars Is Within Reach for Health Systems

A collaborative exercise with 16 health care organizations nets millions in savings.


Rosalind Wong, PharmD Candidate

Latest:

Common Patient Questions About Insulin Biosimilars Pertain to Classification

Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.


Rabiah Dys, PharmD

Latest:

Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?

Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.


Peter Pitts

Latest:

Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?

If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.



Cameron Santoro

Latest:

Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL

A large Chinese study found that HanliKang (HLX01), a biosimilar rituximab, had similar overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).


Pearl Steinzor

Latest:

Dr Ryan Haumschild Draws Link Between Biosimilars, Health Equity in Breast Cancer

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, discusses the growth and continued challenges facing biosimilars used to treat breast cancer.


Paul Cornes, BM, BCH, MA, MRCP, FRCR

Latest:

Column: India Struggles to Meet International Biologics Standards

An internationally recognized authority on biosimilar development discusses varieties of copy biologics in India and the need to distinguish these from true biosimilars.


Robert Popovian, PharmD, MS
Robert Popovian, PharmD, MS

Latest:

Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?

If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.


Meaghan Smith

Latest:

Opinion: Biosimilars Offer Savings and Access for US Patients

In this column, officials from the Biosimilars Forum and Xcenda discuss how biosimilar competition has lowered prices of originator biologics and improved patient access.


Monica Mallampalli, PhD, MSc

Latest:

Biosimilars and Women's Health: Realizing the Potential

The potential and promise of biosimilars are there—it is up to all of us to bring it to reality so we can expand access to safe, effective, affordable drugs for women.


Robert Spina, MBA

Latest:

Opinion: Support Health Equity and Access to Health Care With More Affordable Treatment Options

Changes in federal and state policy can help liberate the savings potential in biosimilars and broaden investment in our health care system.


April Breyer Menon
April Breyer Menon, JD

Latest:

Contributor: The Trouble With IP for Digital Health and Precision Medicine

Two experts in biosimilar intellectual property (IP) law break down the issues that digital health and precision medicine face with IP and the history of case law that has created the current landscape.


Hayden E. Klein

Latest:

Dr Chelsee Jensen Speaks on How Health Systems Can Build Confidence in Biosimilars

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, explains what health organizations and health systems can do to better manage and instill confidence in biosimilars.


Lana Pine

Latest:

Most Israeli Gastroenterologists Prefer Reference Products Over Biosimilars

Although 75% of gastroenterologists believed that the efficacy of biosimilars and biologics were the same, most clinicians still preferred the brand name drug option.


Gillian McGovern

Latest:

House Committee Hearing Addresses PBMs, Anticompetitive Drug Pricing Tactics

The House Committee members examined pricing tactics by PBMs and how they are harming patients across the country.


Camlyn Masuda, PharmD, BCACP, CDCES

Latest:

Common Patient Questions About Insulin Biosimilars Pertain to Classification

Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.


Christopher M. Bruno, JD

Latest:

What We Learned About Biologics on Summer Vacation

Intellectual property law attorneys from the Washington, DC, offices of McDermott Will & Emery LLP, discuss 5 of the most significant trends in biologics litigation that have emerged in recent months.


Bincy P. Abraham, MD

Latest:

Opinion: Embrace the Era of Next-Generation Biologics

Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.


Mike Gladstone
Mike Gladstone

Latest:

Opinion: Efforts to Improve Biosimilars Education Are a Start, but Payer Policies Must Catch Up

Despite improvements in biosimilar education efforts for future health care professionals, payer policies need a major revamp to ensure that biosimilar use is encouraged, according to Pfizer's Mike Gladstone.


Meir Rinde, MS

Latest:

Making Patients in Canada Switch to Etanercept Biosimilars Caused No Harm or Changes in Health Care Use, Study Finds

Health Canada approved biosimilars Brenzys and Erelzi in August 2016 and April 2017, respectively. The study tracked effects of the first phase of the British Columbia Ministry of Health’s Biosimilar Initiative, which required patients to switch to biosimilars starting in May 2019.



St John Skilton, PhD

Latest:

Contributor: The Biosimilars Wave Is Crashing on the Shores of Biopharma Development

St John Skilton, PhD, vice president of product strategy and marketing at Protein Metrics, takes a deep dive into how the development of biosimilars is evolving and how tools, such as mass spectrometry, can help companies keep up with advancing technology.


Robert Zutaut, RPh

Latest:

Pharmacy Can Help Drive Adoption of Rheumatoid Arthritis Biosimilars

Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.


Wayne Winegarden, PhD

Latest:

Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?

If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.

© 2024 MJH Life Sciences

All rights reserved.